Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Maravai LifeSciences Holdings / Equity Bottom-Up

<ul><li>Maravai LifeSciences has emerged as a compelling acquisition target in the life sciences sector,particularly following recent developments and a sharp decline in its market value.</li><li>With its stock having fallen nearly 80% from its 2021 peak, the company has struggled to diversify beyond the COVID-19 vaccine boom.</li><li>However, Maravai's strategic assets and innovative capabilities still hold significant value, making it an attractive prospect for companies like Repligen.</li></ul>

Maravai LifeSciences has emerged as a compelling acquisition target in the life sciences sector,particularly following recent developments and a sharp decline in its market value.With its stock having fallen nearly 80% from its 2021 peak, the company has struggled to diversify beyond the COVID-19 vaccine boom.However, Maravai's strategic assets and innovative capabilities still hold significant value, making it an attractive prospect for companies like Repligen.

Maravai LifeSciences Holdings: Why It Is So Relevant For Repligen & For What Valuation? - Financial Forecasts

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

<ul><li>Maravai is expected to experience returns over the next three years as it matures and grows within the expanding field of next generation medical therapeutics.</li><li>The company has a solid financial foundation, a diverse portfolio of patent-protected products, and a strong position in high growth areas such as mRNA, CAR-T, and CRISPR technology.</li><li>Despite recent market challenges, Maravai's long-term prospects are promising, making it a compelling investment opportunity for patient investors seeking sustained growth and value.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Maravai is expected to experience returns over the next three years as it matures and grows within the expanding field of next generation medical therapeutics.The company has a solid financial foundation, a diverse portfolio of patent-protected products, and a strong position in high growth areas such as mRNA, CAR-T, and CRISPR technology.Despite recent market challenges, Maravai's long-term prospects are promising, making it a compelling investment opportunity for patient investors seeking sustained growth and value.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Maravai Lifesciens Hldgs Inc (MRVI) - Friday, Feb 16, 2024

United States

Maravai LifeSciences Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, focuses on providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai LifeSciences Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Maravai LifeSciences Holdings (MRVI US)

Maravai LifeSciences Holdings: Why It Is So Relevant For Repligen & For What Valuation? - Financial Forecasts

Maravai LifeSciences has emerged as a compelling acquisition target in the life sciences sector,particularly following recent developments and a...

Baptista Research

Maravai Lifesciens Hldgs Inc (MRVI) - Friday, Feb 16, 2024

Maravai is expected to experience returns over the next three years as it matures and grows within the expanding field of next generation medical...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)